Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003

Archives of Internal Medicine

Volumn 168, Issue 18, 2008, Pages 1984-1992

  Hoopes, Andrea J ^a,c   Kammerer, J Steve ^b   Harrington, Theresa A ^a   Ijaz, Kashef ^a   Armstrong, Lori R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NORTHROP GRUMMAN CORPORATION   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG SENSITIVITY; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INFANT; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; TUBERCULOSIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISONIAZID; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS; UNITED STATES;

EID: 54049142917     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.18.1984     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. National action plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep. 1992;41(RR-11):5-48.
2. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2005. Atlanta, GA: US Dept of Health and Human Services; 2006.
3. Francis J. Curry National Tuberculosis Center. Drug-resistant tuberculosis: a survival guide for clinicians. http://www.nationaltbcenter.edu. Accessed July 7, 2008.
4. Scior T, Meneses Morales I, Garcés Eisele SJ, Domeyer D, Laufer S. Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis: a review. Arch Pharm (Weinheim). 2002;335(11-12):511- 525.
5. Bloch AB, Onorato IM, Ihle WW, Hadler JL, Hayden CH, Snider DE Jr. The need for epidemic intelligence. Public Health Rep. 1996;111(1):26-31.
6. American Thoracic Society. CDC; Infectious Diseases Society of America. Treatment of tuberculosis [published correction appears in MMWR Recomm Rep. 2005;53(51):1203]. MMWR Recomm Rep. 2003;52(RR-11):1-77.
7. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR; Tuberculosis Epidemiologic Studies Consortium. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006;173(8):927-931.
8. Moore M, Onorato IM, McCray E, Castro K. Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA. 1997;278(10):833-837.
9. Forssbohm M, Loddenkemper R, Rieder HL. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis. 2003;7(10):973-979.
10. Centers for Disease Control and Prevention (CDC), National Center for HIV/ AIDS, Viral Hepatitis, STD, and TB Prevention. Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC: endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR Recomm Rep. 2006;55(RR-9):1-44.
11. Escalante P, Graviss EA, Griffith DE, Musser JM, Awe RJ. Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest. 2001;119(6):1730-1736.
12. Institute of Medicine. Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.